Cadence Capital Management LLC reduced its holdings in Pfizer (NYSE:PFE) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 363,397 shares of the biopharmaceutical company’s stock after selling 12,371 shares during the quarter. Pfizer comprises 0.8% of Cadence Capital Management LLC’s holdings, making the stock its 18th largest holding. Cadence Capital Management LLC’s holdings in Pfizer were worth $13,162,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Monument Capital Management bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $2,090,000. Clarus Wealth Advisors bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $400,000. Grimes & Company Inc. increased its holdings in shares of Pfizer by 15.8% during the fourth quarter. Grimes & Company Inc. now owns 67,101 shares of the biopharmaceutical company’s stock valued at $2,430,000 after acquiring an additional 9,143 shares in the last quarter. Essex Investment Management Co. LLC increased its holdings in shares of Pfizer by 28.3% during the fourth quarter. Essex Investment Management Co. LLC now owns 24,653 shares of the biopharmaceutical company’s stock valued at $893,000 after acquiring an additional 5,440 shares in the last quarter. Finally, QCI Asset Management Inc. NY increased its holdings in shares of Pfizer by 62.7% during the fourth quarter. QCI Asset Management Inc. NY now owns 5,002 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 1,928 shares in the last quarter. Institutional investors and hedge funds own 71.19% of the company’s stock.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $36,790. The disclosure for this sale can be found here. In the last three months, insiders sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.
PFE stock opened at $36.63 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43. The firm has a market capitalization of $217,220.05, a price-to-earnings ratio of 13.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.90.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The business’s revenue was up .6% on a year-over-year basis. research analysts predict that Pfizer will post 2.95 earnings per share for the current year.
Several equities research analysts have recently commented on the company. Citigroup restated a “sell” rating on shares of Pfizer in a report on Thursday, April 12th. Berenberg Bank restated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, April 11th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. Jefferies Group set a $38.00 price target on Pfizer and gave the stock a “hold” rating in a report on Friday, April 13th. Finally, UBS set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $39.20.
TRADEMARK VIOLATION NOTICE: “Pfizer (PFE) Shares Sold by Cadence Capital Management LLC” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/21/pfizer-pfe-shares-sold-by-cadence-capital-management-llc.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.